NASDAQ · SLS
Healthcare · Biotechnology
$11.66
Down-$0.13 (-1.11%)
Updated Sep 17, 2026, 8:42 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SLS closed at $11.66 after 20 trading sessions, down 15.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $11.24 | $11.735 | $11.24 | $11.66 | 5.13M |
| Sep 15, 2026 | $11.60 | $11.70 | $11.03 | $11.29 | 5.24M |
| Sep 14, 2026 | $10.91 | $12.28 | $10.784 | $11.725 | 10.54M |
| Sep 11, 2026 | $13.55 | $13.74 | $11.38 | $11.545 | 14.71M |
| Sep 10, 2026 | $13.66 | $13.825 | $13.37 | $13.49 | 4.83M |
| Sep 9, 2026 | $13.71 | $14.33 | $13.71 | $13.95 | 5.5M |
| Sep 8, 2026 | $13.77 | $14.37 | $13.32 | $13.96 | 6.06M |
| Sep 4, 2026 | $13.51 | $14.14 | $13.43 | $13.86 | 4.53M |
| Sep 3, 2026 | $14.06 | $14.5442 | $13.55 | $13.70 | 5.78M |
| Sep 2, 2026 | $13.27 | $14.33 | $13.23 | $14.16 | 6.24M |
| Sep 1, 2026 | $13.02 | $13.39 | $12.6401 | $13.22 | 5.91M |
| Aug 31, 2026 | $13.325 | $13.6693 | $12.9386 | $13.34 | 7.45M |
| Aug 28, 2026 | $14.77 | $14.79 | $13.15 | $13.21 | 9.83M |
| Aug 27, 2026 | $14.078 | $15.56 | $13.9157 | $15.21 | 12.12M |
| Aug 26, 2026 | $13.815 | $13.915 | $13.41 | $13.73 | 4.59M |
| Aug 25, 2026 | $14.56 | $15.39 | $13.91 | $14.09 | 8.21M |
| Aug 24, 2026 | $15.475 | $15.48 | $13.91 | $14.325 | 8.82M |
| Aug 21, 2026 | $13.69 | $15.67 | $13.26 | $15.46 | 15.24M |
| Aug 20, 2026 | $13.84 | $14.4364 | $13.01 | $13.40 | 7.82M |
| Aug 19, 2026 | $13.46 | $14.29 | $13.00 | $13.85 | 9.12M |
The latest Smart Investors Daily articles mentioning SLS.
SLS research
Company profile and research snapshot.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 16, 2025 | Maxim Group | Buy | — |
| Nov 22, 2023 | Cantor Fitzgerald | Overweight | — |
| Sep 7, 2023 | Cantor Fitzgerald | Overweight | — |
| Nov 15, 2022 | Alliance Global Partners | Buy | — |
| Jun 28, 2022 | Cantor Fitzgerald | Overweight | — |
Generated Sep 17, 2026, 9:24 PM
SELLAS Life Sciences declined 1.11% today as the broader biotech market digests news about major pharmaceutical companies actively hunting for early-stage cancer assets. While SLS is mentioned alongside other emerging biotech firms in this strategic M&A environment, the modest pullback suggests investors are taking a wait-and-see approach regarding potential acquisition interest.
Bottom line: SELLAS Life Sciences finds itself in a favorable macro environment for early-stage cancer biotechs, but today's modest decline reflects the lack of company-specific catalysts. Investors should monitor upcoming clinical data releases and any M&A discussions, as Big Pharma's heightened acquisition appetite could represent a meaningful opportunity for SLS shareholders in coming quarters.
Yahoo · Sep 15, 2026
J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.
Yahoo · Sep 14, 2026
ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.
Yahoo · Sep 10, 2026
Its IBRX stake jumped 27.5% to 243,678 shares worth $2.13 million, bringing both positions’ combined value to $2.86 million.
Yahoo · Sep 3, 2026
SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLS.
